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Abstract
Glioblastoma multiforme is the most common and lethal primary brain tumor. Glioma progression depends on the
rapid proliferation of tumor cells accompanied by an acute immunosuppressive environment, facilitated mainly by
tumor infiltration of regulatory T cells (Tregs). In this study, we characterize the role of fibronectin, a high–molecular
weight extracellular matrix glycoprotein secreted by tumor cells, in controlling glioma progression and in mediating
immunosuppression. Fibronectin binds to membrane-spanning integrin receptors and plays an important role in cell
signaling, in defining cellular shape, in mobility, and in regulating the cell cycle. We found that inhibition of fibronectin
expression in glioma cells, using short hairpin RNA–mediated silencing of gene expression, delayed cell proliferation
in vitro. This delayed growth is explained, in part, by the observed reduced expression of integrin β1 fibronectin receptor,
which was restored by the inhibition of proteosomal activity. In our analysis of the downstream signaling targets of
integrin β1, we demonstrated reduced phosphorylation of Src kinase and STAT-3. We also observed reduced survivin
expression that induced a three-fold increased accumulation of fibronectin-knockdown cells in the G2/M phase. In an
experimental animalmodel, the fibronectin knockdown tumors had amean survival advantage of 23 days overwild-type
tumors. Moreover, brain samples of animals bearing fibronectin-knockdown tumors showed delayed Treg recruitment.
Collectively, we propose that fibronectin is a key mediator of glioma progression because its inhibition delays both
tumor progression and immunosuppression.
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Introduction
Glioblastoma multiforme is the most common and lethal primary
tumor of the central nervous system in adults, representing more than
50% of the tumors in this category with a survival of 1 to 2 years [1,2].
Glioblastoma development is a bifaceted mechanism that involves
rapid multiplication of tumor cells along with their ability to evade
the immune response due to tumor infiltration of regulatory T cells
(CD4+CD25+Foxp3+, Tregs) [2–6]. Several molecular targets have been
identified which contribute to glioma progression but none of the de-
scribed markers have been identified to be responsible for both tumor
growth and immune suppression. Fibronectin secreted by tumor cells
has been reported to promote brain tumor progression by binding in-
tegrin receptors on tumor cells, although the pathway by which it
acts still remains unclear. In this study, we explain this mechanism by
stable silencing of fibronectin production by GL261 glioma cells using
a specific short hairpin RNA (shRNA). Silencing of fibronectin affects
tumor cell proliferation, which was attributed to the loss of the integ-
rin β1 fibronectin receptors. Activation of Src kinase and STAT-3 was
reduced in fibronectin knocked-down GL261 cells. This delayed
tumor growth by inhibiting survivin expression and Treg infiltration
in brain tumors.
Fibronectin is a high–molecular weight extracellular matrix glyco-
protein secreted by tumor cells [7]. Fibronectin can exist in either sol-
uble plasma form or insoluble cellular form as a part of extracellular
matrix. It is a ligand for the integrin β1 receptors [8,9]. Fibronectin
plays an important role in cell signaling pertinent to tumor progression
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and is important for the proliferation of different types of cancers, in-
cluding glioblastoma [10–12]. Binding of integrins with its ligand trig-
gers downstream signal transduction cascades, of which activation of
Src kinase has been deemed to be important for tumor development
[13,14]. Src kinase is a tyrosine kinase that can be activated by phos-
phorylation at Tyr416. STAT3, a member of the JAK/STAT family, is
one of the several downstream molecular targets of activated Src kinase
[15,16]. STAT3 is considered to be the hub of several signal transduc-
tion pathways in brain tumor development (reviewed by Brantley and
Benveniste [17]). Recent studies by several brain tumor research labora-
tories have identified activated STAT3 to be an important signal trans-
duction regulatory molecule in glioma growth and tumor infiltration
of Tregs [18,19].
We investigated the role played by fibronectin in GL261 mouse
glioma cells. Fibronectin expression in GL261 was knocked down with
shRNA for fibronectin gene. We show delayed growth of fibronectin-
silenced GL261 tumors cells in tissue culture conditions. Fibronectin
knockdown resulted in reduced expression of its receptor, the inte-
grin β1 and consequential inhibition of Src kinase, STAT3 activity,
and survivin expression in GL261 cells. Fibronectin-silenced tumors
exhibited survival advantage in experimental animals over those im-
planted with wild-type GL261 tumor cells. Glioma Treg recruitment
was also slower in the animals that were implanted with the shRNA-
treated cells. These results indicate that fibronectin plays a major role
in brain tumor development by signaling through integrin receptor–
mediated signaling pathways.
Materials and Methods
Animals
Six- to eight-week-old male C57.BL6 (B6) mice were purchased
from Jackson Laboratories (Bar Harbor, ME). All mice were housed
in a specific pathogen-free facility at the University of Chicago, and ex-
periments were conducted according to federal and institutional guide-
lines and with the approval of the University of Chicago Institutional
Animal Care and Use Committee.
Reagents
Tissue culture reagents were obtained from Cellgro/Mediatech
(Manassas, VA) and plasticware from BD Biosciences (San Jose, CA).
shRNA, polymerase chain reaction (PCR), and quantitative PCR
(qPCR) oligos were purchased from Integrated DNA Technologies
(Coralville, IA). pSilencer 4.1-CMV puro vector was purchased from
Ambion/Applied Biotechnologies (Austin, TX). Western blot reagents
and iScript complementary DNA (cDNA) synthesis kit were purchased
from Bio-Rad Laboratories (Hercules, CA). The primary and HRP-
conjugated secondary antibodies for Western blots were obtained from
Cell Signaling Technologies (Boston, MA), Santa Cruz Biotechnol-
ogy (Santa Cruz, CA) and Jackson ImmunoResearch Laboratories
(Westgrove, PA). The RNA isolation kit was obtained from Qiagen
(Valencia, CA) and SYBR Green RT-PCRMaster Mix from Invitrogen
(Carlsbad, CA). Fluorescent-labeled antibodies for flow cytometry
or microscopy were purchased from either BD Biosciences (San Jose,
CA) or eBioscience (San Diego, CA). PP2 Src kinase inhibitor was
purchased from EMD Bioscience (San Diego, CA). The stock solu-
tions of 10 mM PP2 were prepared in DMSO. All other reagents were
purchased from Thermo Fisher Scientific (Pittsburgh, PA), if other-
wise mentioned.
shRNA Cloning and Characterization
The mouse cDNA sequence was analyzed for potential 21nts small
interfering RNA (siRNA) target sequences (Dharmacon Design center;
www.dharmacon.com). Five oligonucleotides and one scrambled siRNA
were first analyzed for suppression of the fibronectin (Table 1), and
siRNA 1 was chosen for maximal activity. The oligonucleotide was re-
designed to have a hairpin loop in the middle and BamH1 and EcoR1
sites at the end and cloned in pSilencer 4.1-CMV puro vector. The
following forward (Fwd) and reverse (Rev) oligonucleotides were used
for fibronectin: Fwd 5′-GATCCGAACAAAGACAGAGACAATT-
TCAAGAGAATTGTCTCTGTCTTTGTTCAGA-3′ and Rev 5′-
AGCTTCTGAACAAAGACAGAGACAATTCTCTTGAAATT-
GTCTCTGTCTTTGTTCG-3′. The oligonucleotides for scrambled
shRNA were Fwd 5′-GATCCGAAACAGAACGAAGAACATT-
TCAAGAGATGTTCTTCGTTCTGTTTCAGA-3′ and Rev 5′-
AGCTTCTGAAACAGAACGAAGAACATCTCTTGAAATGTTC-
TTCGTTCTGTTTCG-3′. Colonies isolated were sequenced to verify
the presence of the insert and the recombinant plasmid was named
FnKD. Scrambled shRNAwas used as vector control (VC) in these ex-
periments. GL261 cells at 80% confluency were transfected with either
FnKD or VC plasmids using Lipofectamine (Invitrogen) as per the
manufacturer’s protocol. Forty-eight hours after transfection, cells were
subjected to puromycin treatment at 1.25 μg/ml to select for stable
transfectants, and selection was continued until the control untransfected
cells were killed. These cells (GL261-FnKD) were then tested for fibro-
nectin knockdown by checking for both messenger RNA (mRNA) and
protein levels and were compared with the GL261-VC cells. For sub-
sequent experiments, transfected cells were cultured in the complete me-
dium that comprised Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum and antibiotics (complete medium).
PCR and qPCR
Silencing of the fibronectin gene was assessed by performing re-
verse transcription–PCR using the cDNA prepared from total RNA of
GL261-FnKD and GL261-VC cells, respectively. RNA was isolated
using the Qiagen RNeasy kit (Qiagen). cDNA was prepared from iso-
lated RNA using the iScript cDNA synthesis kit (Bio-Rad). Primers used
for mouse fibronectin were Fwd 5′-AATCACAGTAGTTGCGGCAG-
GAGA-3′ and Rev 5′-TCTGTCCCAGGCAGGAGATTTGTT-3′.
mRNA transcript levels of selected genes in GL261-VC and GL261-
FnKD cells were tested by qPCR. Expression of mouse itgb1 (Fwd
5′-TGTGACCCATTGCAAGGAGAAGGA-3′ and Rev 5′-AATTG-
GGATGATGTCGGGACCAGT-3′) and survivin (birc5) (Fwd 5′-
TTGAGGCCCTAGGTTCAATTCCCA-3′ and Rev 5′-AGCTGCT-
CAATTGACTGACGGGTA-3′) was studied using cDNA prepared
from total RNA of GL261-VC and GL261-FnKD cells. qPCR was
performed using Bio-RadOpticon 2 real-time PCRmonitor with SYBR
GreenER qPCR Master Mix (Invitrogen). All reactions were performed
Table 1. List of siRNA Oligonucleotides Tested to Inhibit Fibronectin Expression in GL261
Mouse Glioma Cells.
siRNA Oligo Exon
siRNA 1 5′-GAACAAAGACAGAGACAA-3′ 36
siRNA 2 5′-GAACAAACACTAACGTAAA-3′ 45/46
siRNA 3 5′-ACTATTAGCTGGAGAACAA-3′ 36
siRNA 4 5′-GAACAAGACCAGAAGTATT-3′ 8
siRNA 5 5′-GGAACTGACTGATGTGAAA-3 19
Scrambled 5′-GAAACAGAACGAAGAACA-3′
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in triplicate. Expression of each target gene was normalized to gapdh
(Fwd 5′-TCAACAGCAACTCCCACTCTTCCA-3′ and Rev 5′-ACC-
CTGTTGCTGTAGCCGTATTCA-3′). Fold expression was calculated
using the 2−ΔΔCTmethod [20].
Western Blots
Inhibition of fibronectin protein expression was assessed by Western
blot using the cell lysates from GL261-FnKD and GL261-VC cells.
Briefly, 1 × 106 cells of each type were lysed using M-PER mammalian
protein extraction reagent with 1× Halt protease inhibitor cocktail and
phosphatase inhibitor (Thermo Fisher Scientific). One hundred micro-
grams of protein from the cell lysates was denatured in the presence
of β-mercaptoethanol and SDS at 100°C and loaded into each well
of a Tris-HCl Precast Ready Gel for SDS-PAGE (Bio-Rad) and sepa-
rated by electrophoresis. Separated peptides were then transferred on
to a polyvinylidene difluoride membrane by semidry transfer blot
(Bio-Rad). Transferred membranes were blocked with 5% nonfat milk
in TBST (100 mM Tris and 150 mM NaCl [pH 7.4] with Tween-20)
for 1 hour at room temperature and incubated overnight at 4°C with
antibodies against mouse fibronectin. Antibody-treated membranes
were washed with 1× TBSTand reincubated with HRP-conjugated sec-
ondary antibody for 1 hour at room temperature. Immunoreactive
bands were developed using the Immun-StarWestern C chemilumines-
cence reagent (Bio-Rad) and visualized by chemiluminescent camera in a
Bio-Rad gel documentation system. Lysates from GL261-FnKD and
GL261-VC cells were also used to detect the expression of phosphory-
lated Src kinase (phospho-Src [Tyr416]) and phosphorylated STAT3
(phospho-STAT3 [Tyr705]) and survivin protein levels using respec-
tive mouse-specific antibodies. The expression of total Src and STAT3
was used to measure the loading control for phospho-Src (Tyr416) and
phospho-STAT3 (Tyr705), respectively. The expression of β-actin was
used as a loading control for survivin expression.
In Vitro Labeling of Cultured Cells with Bromodeoxyuridine
GL261-FnKD and GL261-VC cells (50,000 cells per well) were
plated in each well of a six-well tissue culture plate overnight in com-
plete medium. On the next day, the medium was replaced with com-
plete medium containing 10 μM of bromodeoxyuridine (BrdU; BD
Biosciences). The cells were harvested at 24, 72, and 108 hours after
the addition of BrdU and were stained according to the manufacturer’s
protocol. In brief, the cells were fixed and permeabilized, followed by per-
meabilization of the nuclear membrane, and finally refixed. The DNA
was fragmented using DNAse I, and BrdU incorporation was detected
by staining using a fluorescein isothiocyanate (FITC)–conjugated anti-
BrdU monoclonal antibody (1:50). Mouse IgG1κ-FITC was used as
the isotype control. Cells that were not treated with BrdU were tested
as the experimental control. The cells were then analyzed by flow cytom-
etry using BDFACSCalibur (BDBiosciences) and FlowJo software (Tree
Star Inc, Ashland, OR). The experiment was conducted in triplicate
wells and performed thrice. Similar experiments were performed in
which cells were cultured in either serum-free medium or serum-free
medium supplemented with 25 μg/ml of purified soluble bovine fibro-
nectin (Sigma, St Louis, MO).
Flow Cytometry
The levels of integrin β1 on GL261-VC and GL261-FnKD cells
were analyzed by flow cytometry. Briefly, cells were grown in 25-cm2
tissue culture flasks up to 50% confluency. The cells were harvested
using a cell scraper to prevent trypsin-induced ablation of the integrins
and was performed on ice to prevent internalization of the same. Har-
vested cells were fixed immediately with 1% paraformaldehyde and
stained with anti-mouse integrin β1 antibodies conjugated with phy-
coerythrin (PE; 1:200). Hamster IgG-PE was used as antibody con-
trol. After incubation, the cells were washed twice with FACS buffer
(PBS +1% BSA +0.02% NaN3), and the expression of integrin β1
was analyzed by flow cytometry.
MG132 Treatment of GL261 Cells
Fifty thousand GL261-VC or GL261-FnKD cells were plated in
each well of a 24-well plate and cultured in complete medium under
normal tissue culture conditions. After 24 hours, the medium was re-
placed with fresh medium, which was supplemented with 5 μM
MG132 and incubated for 1, 2, and 5 hours under normal conditions.
After incubation, the cells were harvested using cell scrapers on ice.
Levels of integrin β1 were assessed by method as described above.
Cell Cycle Assay
To elucidate the delay in cellular proliferation, we performed a cell
cycle analysis. Twenty thousand GL261-VC and GL261-FnKD cells
were plated in each well of a 24-well plate and cultured in complete
medium under regular tissue culture conditions for 48 hours. After in-
cubation, the cells were washed twice with ice-cold PBS and fixed in
ice-cold methanol. Fixed cells were rehydrated back with two washes
of PBS and treated with RNase (100 μg/ml; Sigma) for 15 minutes
at 37°C. The reaction was stopped by diluting it with three volumes
of PBS. Propidium iodide (50 μg/ml; eBioscience) was added to the
RNase-treated cells, and propidium iodide dilution was analyzed im-
mediately by flow cytometry.
Src Kinase Inhibition and Survivin Expression
The role of Src kinase activity in survivin expression was tested in
GL261 cells using PP2 Src kinase inhibitor. Briefly, 2 × 105 cells were
plated in each well of a six-well tissue culture plate and were cultured
exactly for 12 hours in complete medium supplemented with PP2
(0-15 μM). DMSO was used as vehicle control. After incubation, the
cells were lysed, and Western blot was performed as described earlier
using antimouse survivin antibody.
Intracranial Tumor Implantation
Male B6 mice were anesthetized with an intraperitoneal injection
of ketamine hydrochloride (25 mg/ml)/xylazine (2.5 mg/ml) cock-
tail. A midline cranial incision and a right-sided burr hole were made
2 mm lateral to the sagittal sinus and approximately 2 mm superior to
the lambda. The animals were positioned in stereotactic frame, and a
Hamilton needle was then inserted into the burr hole and advanced
3 mm. Intracranial penetration was followed by the injection of 4 ×
105 cells in 2.5 μl of sterile PBS. One group of five animals was injected
with the GL261-VC cells, whereas a second group with the same
number of animals received GL261-FnKD cells. All animals were kept
under observation to assess survival.
Similar experiments were performed in which two groups of animals
were implanted with GL261-VC and GL261-FnKD cells, respectively,
and three animals per group were killed on the 7th, 14th, and 21st day
post implantation (PI). Brain tissues around the tumor injection site
were harvested from each animal for further studies.
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Histology
Twenty-one days after tumor implantation, mouse brains were har-
vested, flash frozen, sectioned at a thickness of 8 μm, and thaw-
mounted (37°C for 5-10 minutes) onto precleaned SuperFrost slides
(Thermo Fisher Scientific). The slides were stained with hematoxylin
and eosin to visualize the brain tumors and were dehydrated sequen-
tially as follows: alcoholic formalin (30 seconds), H2O (10 dips), hema-
toxylin (filtered Gill 3; 2 minutes), H2O × 2 (10 dips), bluing solution
(60 seconds), H2O (10 dips), alcoholic eosin (10 dips), 95% EtOH ×
2 (10 dips), 100% EtOH × 2 (10 dips), and xylene × 3 (10 dips). Sec-
tions were covered with Permount, coverslipped, and viewed using a
Zeiss Axioskop microscope (Carl Zeiss, Hamburg, Germany). Images
were captured using Improvision’s OpenLab software (PerkinElmer,
Waltham, MA) microscope attached to a Zeiss Axiocam CCD camera
and image capturing system (Carl Zeiss).
Survivin Expression in Tumor-Implanted Brain
To analyze whether survivin played any role in tumor growth in vivo,
qPCR for survivin mRNA transcript levels was performed with cDNA
prepared from the brain tissues that were harvested from the injection
site of GL261-VC and GL261-FnKD tumor-implanted animals at 7,
14, and 21 days after tumor implantation. qPCR was performed as de-
scribed earlier. The expression of survivin (birc5) was normalized to
gapdh. Fold expression was calculated using the 2−ΔΔCTmethod [20].
Analysis of Treg Infiltration in Tumor-Implanted Brains
The effects of fibronectin silencing on Treg were studied in tumor-
implanted brains harvested at 7, 14, and 21 days PI. Brains were
harvested, and cells were resuspended in staining buffer (1× Hank’s bal-
anced salt solution, 1% bovine serum albumin, 0.02% sodium azide)
after red blood cell was lysed using ACK lysing buffer. Brain cells were
stained with anti–CD4-FITC monoclonal antibody (1:200) for surface
CD4 expression, and intranuclear expression of FoxP3 was assessed by
staining with anti–FoxP3-APC monoclonal antibody (1:100) after per-
meabilizing and fixing the cells with FoxP3 staining kit (eBioscience).
Respective isotype controls were used for each antibody. Treg infiltra-
tion was then analyzed by flow cytometry.
Statistical Analysis
GraphPad Prism software package for Windows (version 4.0; Graph-
Pad Software, Inc, La Jolla, CA)was used to run analysis of variance, two-
tailed unequal-variance t test, and Student’s t test, and SD and SEM of
the data were presented. A value of P < .05 was considered significant.
Results
Stable Knockdown of Fibronectin Expression in GL261
Glioma Cells
GL261 mouse glioma cells were transfected with a plasmid encoding
mouse fibronectin-silencing shRNA (FnKD) or scrambled shRNA
(VC). The fibronectin shRNAwas chosen from a set of five siRNA oligo-
nucleotides that were tested for their efficiency in inhibiting fibronectin
expression (Table 1). Transfected cells were selected by puromycin treat-
ment and a positive clone was selected when the nontransfected cells were
killed by the antibiotic treatment. Reverse transcription–PCR for fibro-
nectin expression in the GL261-FnKD cells did not show any amplified
product when compared with those of the GL261-VC cells (Figure 1A).
Similar results were observed when Western blots were performed with
the lysates from GL261-VC and GL261-FnKD cells and probed with
the anti-fibronectin antibody. GL261-VC lysates showed the fibronectin
band, whereas it was absent in the GL261-FnKD lysates (Figure 1B).
These results confirm that fibronectin expression is stably silenced in
the GL261-FnKD cells.
Fibronectin Knockdown Delays Glioma Proliferation
Glioma progression depends on the exponential growth of tumor
cells. Under regular culture conditions, the GL261-FnKD cells showed
very slow growth in comparison to the GL261-VC or the GL261-wild
type cells, which warranted a BrdU uptake assay. BrdU uses nucleotide
substitution to replace thymidine with uridine in the DNA structure of
dividing cells both in vitro and in vivo. Equal numbers of GL261-VC
and GL261-FnKD cells were cultured with 10 μM BrdU in complete
medium for 24, 72, and 108 hours and BrdU uptake was analyzed by
flow cytometry after fixing and staining the cells with anti-BrdU anti-
body. Although there was no difference in BrdU uptake between the
two groups at 24 hours, a rapid increase in BrdU accumulation was
observed in GL261-VC cells after 72 hours and was further increased
at 108 hours. In contrast, the GL261-FnKD cells failed to significantly
incorporate BrdU even at 108 hours (Figure 2A).
Similar experiments were performed in which serum-free Dulbecco’s
modified Eagle medium was used in place of complete medium to in-
vestigate the role of serum-associated soluble plasma fibronectin in gli-
oma proliferation. Levels of BrdU incorporation were reduced in both
GL261-VC and GL261-FnKD in the absence of serum at all of the
time points studied (Figure 2B).
Purified soluble fibronectin was supplemented to the serum-free me-
dium in a third set of experiments. Incorporation of BrdU by GL261-
VC cells was recovered to an intermediary level in the presence of soluble
fibronectin. However, GL261-FnKD cells showed no signs of increase
in proliferation (Figure 2C).
Figure 1. Fibronectin knockdown using shRNA. shRNA was de-
signed to silence the mouse fibronectin gene and was cloned in an
shRNA-expressing plasmid and transfected in GL261 mouse glioma
cell line (GL261-FnKD). Cells transfected with scrambled plasmid
were used as vector control (GL261-VC). (A) Expression of fibronectin
gene in the GL261-VC and GL261-FnKD as observed by PCR using
cDNA prepared from stably transfected cells. (B) Western blot band
for fibronectin protein in cell lysates of GL261-VC and GL261-FnKD
cell lysates. β-Actin protein was used as the loading control.
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Expression of β1 Integrin Is Reduced in GL261-FnKD Cells
A major receptor for fibronectin on tumor cells is the membrane-
spanning integrin β1 [9]. Failure of GL261-FnKD cells to respond to
soluble plasma fibronectin or purified soluble fibronectin prompted
us to check the levels of integrin β1 in these cells. GL261-VC and
GL261-FnKD cells were stained with PE-conjugated anti-β1 anti-
body. Flow cytometric analysis revealed reduced mean fluorescence
intensity (MFI) of integrin β1 expression in GL261-FnKD cells when
compared with those of GL261-VC cells (Figure 3A). However, no
significant difference in mRNA transcript levels of itgb1 gene expres-
sion was observed between the GL261-VC and GL261-FnKD cells
(Figure 3B).
Figure 3. β1 Integrin expression in glioma cells. (A) Flow cytometry profile of cell surface expression of β1 integrin on GL261-VC (open
histogram) and GL261-FnKD cells (dark gray histogram). Hamster IgG was used as antibody control (light gray histogram). (B) Fold change
in itgb1mRNA transcript levels in GL261-FnKD cells (black bar) with respect to GL261-VC (white bar) measured by quantitative PCR. (C) MFI
of cell surface β1 integrin expression calculated from flow cytometric analysis of GL261-VC cells treated with MG132. (D) MFI of cell surface
β1 integrin expression calculated from flow cytometric analysis of GL261-FnKD cells treated with MG132. A 1.5-fold increase in MFI was
observed after 2 hours of treatment, and a 3.2-fold increase was observed after 5 hours. (E) Bar diagram comparing MFI of cells surface
β1 expression between GL261-VC (white bar) and GL261-FnKD (black bar) cells treated with MG132 for 5 hours. Error bars for all figures
represent SD within triplicate observations.
Figure 2. BrdU uptake assay. BrdU uptake is often used as a marker for cell proliferation because it is rapidly taken up by dividing cells, and
accumulates in these cells since it is not metabolized. (A) GL261-VC or GL261-FnKD cells were incubated with BrdU in complete medium for
different time points. (B) Cells incubated with BrdU in serum-free media. (C) Cells incubated with BrdU in serum-free medium, which was
supplementedwith 25 μg/ml of purified fibronectin. BrdU uptakewas analyzed as described inMaterials andMethods. Percentage values of
BrdU-positive cells plotted in a bar graph showing BrdU-positive GL261-VC cells (white bars) versus GL261-FnKD cells (black bars) at similar
time points. Error bars represent SD within triplicate observations.
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MG132 Treatment Facilitates Integrin β1 Expression in
GL261-FnKD Cells
We tested the effects of MG132, a potent inhibitor of proteosomal
activity, on the reversal of integrin β1 protein expression in GL261-
FnKD cells. Both GL261-VC and GL261-FnKD cells were incubated
for 5 hours in the presence of 5 μMMG132. Integrin β1 expression in
GL261-VC cells was not affected by the treatment (Figure 3C ). How-
ever, in GL261-FnKD cells, there was a 1.5-fold increase in integrin β1
expression after 2 hours, which increased up to 3.2-fold when the cells
were incubated for 5 hours with MG132 (Figure 3D). Five hours of
treatment with MG132 increased the MFI of integrin β1 expression in
GL261-FnKD cells to the same levels of GL261-VC cells (Figure 3E).
Src Kinase and STAT-3 Activity Are Downregulated in
Fibronectin Knockdown GL261 Cells
Integrins signal through Src kinase and play an important role in
tumor progression [13,14,21]. We wanted to test the status of Src kinase
expression in GL261-FnKD cells. Western blot results showed complete
abrogation of phospho-Src (Tyr 416) in GL261-FnKD cells. Clean
bands of phospho-Src (Tyr416) were, however, observed in GL261-
VC cell lysates (Figure 4A). Because Src kinase is the first major molecule
in the downstream signaling cascade of integrin receptors, its loss further
indicated that integrin β1 was downregulated in GL261-FnKD cells.
STAT-3 is a downstream target for Src kinase [15,16,22,23]. It is also
an important oncogene promoting transcription control, cell cycle pro-
gression and cellular transformation [24,25] and is a target for cancer
target drug discovery [26]. STAT3 is also an important marker for
glioma progression and is under intense investigation [19,27–31]. The
status of STAT3 activation in GL261-FnKD cells was analyzed by
Western blot. Results demonstrated reduced levels of phospho-STAT3
(Tyr705) in GL261-FnKD cells with respect to GL261-VC cells
(Figure 4B).
G2/M Block in the GL261-FnKD Cell Cycle Pathway
Delay in GL261-FnKD cell growth required us to look at the cell
cycle status of these cells. GL261-VC and GL261-FnKD cells were cul-
tured for 48 hours in complete medium, and cell cycle analysis of these
cells was performed according to Materials and Methods. The results
showed a three-fold increase in accumulation of GL261-FnKD cells in
the G2/M phase in comparison to the GL261-VC cells. The GL261-VC
cells, however, were mostly in the G0/G1 and S phases (Figure 5A).
Reduced Survivin Expression in GL261-FnKD Cells
Survivin is a member of inhibitor of apoptosis protein family. It
is known to facilitate mitosis and drive cells into the S phase. Over-
expression of survivin has often been shown to result in accelerated S
phase shift and vice versa [32]. Survivin has also been reported to be
one of the most important proliferation markers of glioma [33–35].
qPCR analysis of survivin (birc5) mRNA transcript level demonstrated
five-fold lower level in GL261-FnKD cells when compared with that
of GL261-VC cells (Figure 5B). Western blot for survivin protein ex-
pression mirrored the qPCR observation. Reduced expression of sur-
vivin protein was observed in GL261-FnKD cells (Figure 5C).
Survivin Expression in GL261 Cells Is Regulated by Src
Kinase Activity
To draw a link between the integrin β1 signaling and survivin activ-
ity, we tested the role of Src kinase activation in survivin expression in
glioma. Survivin has also been shown to be a downstream target of Src
kinase/STAT-3 pathway, which further warranted this investigation
[36,37]. GL261-VC cells were treated for 12 hours with the increas-
ing concentrations (0-15 μM) of PP2 to block Src kinase activity. Sur-
vivin protein expression was analyzed by Western blot and showed
decreasing survivin expression with increasing concentrations of PP2
(Figure 5D).
Increased Survival of GL261-FnKD
Tumor-Implanted Animals
Intracranial implantation of either GL261-VC or GL261-FnKD was
performed in two groups of five B6 mice. The first casualty of the
GL261-VC–implanted group was recorded on the 23rd day PI, and
all animals in this group succumbed to the tumor by the 42nd day
PI. However, the first death in GL261-FnKD–implanted animals was
on 42nd day PI, and final death was recorded on the 64th day PI.
Kaplan-Meier survival curve demonstrated a 23-day survival advantage
of GL261-FnKD–implanted animals versus GL261-VC (Figure 6).
Lower Survivin Expression and Delay in Tumor
Development In Vivo
Histopathology of tumor development was performed by staining
brain sections with hematoxylin and eosin. Implantation of GL261-
VC cells led to reproducible tumor growth by the 21st day PI, which
is evident by the buildup of basophilic stained cells around the in-
jection site. Although injected cells were observed in GL261-FnKD–
implanted brains, typical tumor formation was never observed at
identical time point (Figure 7, A and B).
Previous experiments showed reduced survivin expression in GL261-
FnKD cells grown in vitro (Figure 5, B and C ). We observed similar
pattern of reduced survivin (birc5) mRNA transcripts levels in GL261-
FnKD tumor-implanted brains when compared with those of GL261-
VC–implanted brains. Tumor-implanted animals were killed on days 7,
14, and 21 PI. The right posterior section of the brain that was injected
with tumor cells was harvested from animals to prepare cDNA from total
RNA. qPCR results showed roughly 2- to 2.5-fold decrease in the tran-
scription of survivin (birc5) in GL261-FnKD–implanted brains at all the
time points observed when compared with GL261-VC (Figure 7C).
Figure 4. Reduced Src kinase and STAT3 activity in GL261-FnKD
cells. (A) Western blots for phospho-Src (Tyr416) in GL261-VC and
GL261-FnKD cell lysates. Expression of total Src levels wasmeasured
as loading control. (B) Phospho-STAT3 (Tyr705) in GL261-VC and
GL261-FnKD cells. Total STAT3 expression was used as a control.
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Delay in Treg Recruitment in
GL261-FnKD–Implanted Brains
Delayed in vivo tumor growth was further evidenced by a lag in Treg
recruitment in the GL261-FnKD implanted brains (Figure 8). The
expression of FoxP3+-expressing CD4+ T cells in brain tumors was
analyzed after the 7th, 14th, and 21st day PI. Although on the 7th day,
the difference in Treg recruitment was not significant, the level of FoxP3
expression by CD4+ T cells in GL261-FnKD–implanted brains at 14th
day was almost 2.2-fold lower than that in GL261-VC tumors. After
21 days, the difference was increased to almost 2.6-fold with 63.4% of
CD4+ T cells expressing FoxP3 in GL261-VC tumors, whereas 24.8%
CD4+ T cells expressed FoxP3 in GL261-FnKD tumors.
Discussion
Fibronectin in brain tumors was first described by Sherbet et al. [11]
and has been primarily associated with cell migration upon binding
with integrin receptors [12]. The expression of fibronectin and other
extracellular matrix components by glioma is directly linked to the
expression of integrins on cell surface. Ritchie et al. [38] showed that
in glioma cells with induced and ectopic expression of nuclear factor
κB, there was an increase in the expression of both fibronectin and
integrins. More recently, fibronectin has been reported to maintain
extracellular matrix rigidity to promote structural rigidity, motility, and
proliferation of established glioma cell lines in vitro [39]. However, the
functional mechanism of fibronectin-mediated regulation of glioma
progression has remained unknown.
Fibronectin expression in GL261 glioma cells was silenced with
the introduction of shRNA targeted toward the mouse fibronectin
gene in the cells (Figure 1). Inhibition of fibronectin expression in
GL261 glioma cells (GL261-FnKD) delayed cell proliferation in vitro
in comparison to the GL261 cells that were treated with scrambled
shRNA (GL261-VC). When GL261-FnKD cells were implanted in
the brain of experimental animals, a delay in tumor formation was
observed (Figure 7A), and these animals exhibited a 23-day survival
Figure 6. Fibronectin knockdown in glioma cells prolongs survival
time of tumor implanted animals. Kaplan-Meier survival curve for
two groups of B6 mice implanted intracranially with GL261-VC (solid
line) and GL261-FnKD (broken line) tumors, respectively. Five ani-
mals were included in each group. Mean survival time of GL261-
VC–implanted animals was 30 days, whereas it was 53 days for
GL261-FnKD–implanted group.
Figure 5. Survivin expression in GL261-FnKD cells. (A) Cell cycle assay with propidium iodide incorporation for 48 hours in culture. White
bars represent GL261-VC cells, and black bars represent GL261-FnKD cells. Three-fold higher levels of propidium iodide–positive GL261-
FnKD cells were observed in the G2/M phase. Error bars represent SD within six replicate observations. (B) Fold change in the mRNA
transcript level of survivin (birc5) between GL261-VC (white bars) and GL261-FnKD (black bars) measured by quantitative PCR. Error bars
represent SD between triplicate qPCR observations. (C) Immunoblot for survivin expression in GL261-VC and GL261-FnKD cell lysates.
β-Actin was used as a loading control. (D) Western blot for survivin protein expression in GL261 cells after treatment with PP2 (0-15 μM).
DMSO was used a vehicle control (VC). β-Actin was used as loading control.
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advantage over the GL261-VC–implanted ones (Figure 6). Our obser-
vation is the first report linking fibronectin with in vivo tumor growth
and survival of experimental animals.
We performed a BrdU uptake assay to monitor the delay in cell
growth. BrdU uptake is often used as a marker for cell proliferation
because it is rapidly assimilated by dividing cells [40,41]. The results
showed that the slow-growing GL261-FnKD cells accumulated lower
amounts of BrdU over time, whereas the GL261-VC cells incorporated
increasing amounts of BrdU at comparable time points (Figure 2A). It
is important to note here that GL261-FnKD cells showed lesser in-
corporation of BrdU in the presence of serum, which is a rich source
of soluble plasma fibronectin. We performed experiments to show
the importance of soluble fibronectin in glioma cellular proliferation.
In one such experiment, GL261-VC failed to accumulate any BrdU
in serum-free condition (Figure 2B). This observation was partially
recovered by supplementing the serum-free medium with purified
soluble fibronectin. These experiments were done in the presence of
25 μg/ml of purified fibronectin because it was the optimal concentra-
tion found in bovine serum [42]. The levels of BrdU incorporated
by GL261-VC cells increased partially in response to the purified fi-
bronectin (Figure 2C ). These observations indicated that soluble fi-
bronectin was important for glioma cellular proliferation. However,
fibronectin-silenced GL261-FnKD failed to respond again, even in the
presence of purified soluble fibronectin.
Extracellular fibronectin is a ligand for integrin receptors on tumor
cell surface [8,43]. Integrin β1 has been shown to be a major cell sur-
face receptor for glioma and to play important roles in glioma progres-
sion [9]. The inability of GL261-FnKD cells to respond to soluble
fibronectin warranted further investigation of the status of the integrin
β1 fibronectin receptors in these cells. We measured integrin β1 expres-
sion by qPCR for its mRNA transcript levels followed by flow cytome-
try to assess the cellular protein expression. We observed a decrease
in the MFI of integrin β1 expression in the GL261-FnKD cells in com-
parison to the GL261-VC cells (Figure 3A). This phenomenon ex-
plained the lack of response by GL261-FnKD to plasma-associated
and purified soluble fibronectin. However, we could not detect any dif-
ference between the itgb1mRNA transcript levels between the GL261-
VC and GL261-FnKD cells (Figure 3B). This indicated that silencing
of fibronectin expression caused a posttranscriptional inhibition of
integrin β1 fibronectin receptor. We tested this hypothesis by inhibit-
ing proteosomal degradation of integrin β1 expression by treating cells
with MG132, an irreversible proteosomal inhibitor. The inhibitor did
not have any effect on the integrin β1 expression in the GL261-VC
cells (Figure 3C). However, the MFI of integrin expression in GL261-
FnKD cells increased by 3.2-fold after incubating the cells for 5 hours
with the inhibitor (Figure 3D). In fact, similar levels of integrins were
expressed in both GL261-VC and GL261-FnKD cells after 5 hours
of treatment with MG132 (Figure 3E ). These results indicated that
shRNA-mediated inhibition of fibronectin expression in GL261 glioma
cells induced a posttranscriptional degradation of the integrin β1 fibro-
nectin receptors by activation of proteosomal enzymes. It is important
to note here that integrin β1 has been shown to be required for dif-
fuse brain invasion of glioma cells in an experimental rat glioma model
[44]. Our results also correlate with this observation, and the lack of
integrin β1 expression might contribute to the delay in tumor growth
and increased survival of GL261-FnKD–implanted animals (Figures 6
and 7, A and B). However, we believe that in addition to glioma invasion,
the delayed proliferation of glioma cells in these animals played an even
Figure 7. Tumor development and survivin transcript levels in experimental animals. (A) Hematoxylin-eosin (HE) staining of tumor-
implanted brain sections at 21st day PI. Harvested brains were sectioned through the site of tumor implant, and tumor distribution was
observed under microscope. Scale bars indicate 500 μm. (B) Upper panel shows higher-magnification image of the primary injection site
in the HE-stained sections of GL261-VC (left) and GL261-FnKD (right) tumor implanted brain. Lower panel shows the tissue distribution at
the glioma border in the tumor-implanted HE-stained brain sections. Scale bars indicate 100 μm. (C) Fold change in mRNA transcript level
of survivin (birc5) in GL261-VC– (white bars) and GL261-FnKD–implanted (black bars) brains at 7, 14, and 21 days PI. Error bars represent
SEM of observations obtained from three animals per treatment group.
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more important role in increased survival. We further investigated the
role of integrin β1 in glioma cell proliferation.
Degradation of integrin β1 in GL261-FnKD cells was predicted to
affect integrin-induced proliferation signals. Our hypothesis was con-
firmed when the activated phospho-Src (Tyr416), a downstream target
of integrin signaling [13,14], was almost obliterated in GL261-FnKD
cells (Figure 4A). Next, we tested the activation of STAT3 in GL261-
FnKD cells because of two reasons: first, Src kinase is one of several
regulators of STAT3 function [16,22], and second, activated STAT3
is a vital marker for glioma progression [19,29–31]. Our hypothesis
of reduced STAT3 activity in GL261-FnKD cells was confirmed by
the absence of the activated phospho-STAT3 (Tyr705) in these cells
(Figure 4B). We performed a cell cycle assay to understand the relation
between degradation of integrin receptors and delay in proliferation of
the GL261-FnKD cells. Analysis of the data acquired from these ex-
periments revealed three-fold more accumulation of the slow growing
GL261-FnKD cells in the G2/M phase. In comparison, the GL261-
VC cells were mostly in the S phase indicating their active proliferation
(Figure 5A). This observation suggested a defect in proliferation regula-
tors of GL261-FnKD cells.
Survivin or baculoviral inhibitor of apoptosis repeat containing 5
(birc5) is a member of the inhibitor of apoptosis family [45]. Survivin
is observed uniquely in tumor and developmental cells, which un-
dergo either inappropriate or programmed cell growth [46]. Survivin
Figure 8. Treg infiltration is affected in GL261-FnKD–implanted brains. (A) Flow cytometric measurement of FoxP3+ CD4+ T cells’ infiltra-
tion in tumor-implanted brains at 7th, 14th and 21st day PI. CD4 is distributed along the y axis, whereas FoxP3 is along the x axis of the
plots. These observations are derived from total CD4+ T cells derived from each tumor-implanted brain. Quadrants were drawn based on
the isotype staining for each antibody. Numbers in each quadrant represent respective distribution frequency. Treg infiltration in GL261-
VC tumor-implanted brains (top panel) is compared with GL261-FnKD–implanted brains (lower panel). This figure represents one of three
animals per group at each time point. (B) Bar diagram representation of CD4+ T cells that express FoxP3 in tumor-implanted brains. FoxP3
expression was increased by 2.2-fold in GL261-VC tumor-implanted brains (white bars) over GL261-FnKD tumor-implanted brains (black
bars) by 14 days PI and increased to 2.6-fold at 21 days. Error bars indicate SEM of three or more replicate animals per group at their re-
spective time points.
Neoplasia Vol. 12, No. 10, 2010 Fibronectin Regulates Glioma Progression Sengupta et al. 845
participates in cell cycle entry and progression by binding with mitotic
spindle fibers and by facilitating the cells to roll into the S phase and
controlling apoptosis by inhibiting caspase activation [32,47]. Survivin
has been identified as an important oncogene for glioblastoma promot-
ing tumor proliferation, and inhibition of survivin in U251 glioma cells
has been reported to exhibit decreased cell growth and cell cycle arrest
[33,34]. Moreover, survivin has also been shown to be a downstream
target of Src kinase and STAT3 activity in different types of cancer
[36,37,48,49]. As such, we sought to study the status of survivin in
GL261-FnKD cells over other proliferation markers. We observed de-
creased survivin expression, both at the mRNA transcript and protein
levels (Figure 5, B and C). These results corroborated with the earlier
reports that noted the importance of survivin in glioma progression
[33,35]. Our observation also agreed with the recent report published
by Mellai et al. [34], in which the authors observed that survivin ex-
pression in glioma cases positively correlated only with tumor prolif-
eration, whereas it failed to show any correlation with apoptosis. We
further demonstrated that survivin expression in glioma was directly
related to the Src/STAT3 pathway by treating GL261 cells with the
PP2 Src kinase inhibitor. Western blot with the PP2-treated cell ly-
sates showed decreased levels of survivin protein (Figure 5D). This
result matched with the recently reported observation of Src kinase–
dependent survivin expression in osteosarcoma [37]. We further tested
the expression of survivin in animal models implanted with tumors. A
two-fold decrease in survivin mRNA transcript levels was observed in
murine brains bearing GL261-FnKD tumors when compared with
those of GL261-VC–implanted brains during the first 3 weeks after
tumor implantation (Figure 7C ). These observations confirmed that
fibronectin silencing aborted integrin signaling in GL261 cells and
failed to initiate Src kinase and STAT3 activity, thus aggressively reduc-
ing survivin expression.
A major cause of brain tumor progression is increased Treg infiltra-
tion in the tumor [4,5]. We measured Treg infiltration in the tumor-
implanted brains of experimental animals by flow cytometry (Figure 8).
A gradual but definitive increase in Treg accumulation was observed in
animals’ brains implanted with GL261-VC tumors as early as 14th day
PI. At the 21st day PI, Tregs accounted for 63.4% of all the CD4+ T
cells in the brain. This observation correlated with proliferative increase
in tumor growth and survival of the GL261-VC–implanted animals.
In comparison, Treg infiltration in GL261-FnKD–implanted brains
was slower and accumulated 2.6-fold less Tregs than the GL261-VC–
implanted animals by the 21st day PI. These observations indicated
a reduced immunosuppressive environment in fibronectin-silenced tu-
mors. These observations also demonstrated that Treg infiltration was
dependent on the tumor growth and corroborated with recent obser-
vations by Grauer et al. [50], in which the authors reported gradual
accumulation of Tregs during tumor growth.
Collectively, we conclude that this study for the first time contributes
toward understanding the role of fibronectin in glioma progres-
sion. It explains the mechanism that involves the maintenance of integ-
rin β1 fibronectin receptors in glioma cells required by fibronectin to
induce a Src kinase–dependent survivin activity that promotes brain
tumor proliferation.
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